Tirzepatide is an FDA-approved injectable medication indicated for chronic weight management in adults with obesity or overweight, as well as for the treatment of type 2 diabetes.

Research Information | Health Resources

The efficacy of Tirzepatide for weight management was notably evaluated in the SURMOUNT-1 clinical trial, a phase 3 double-blind, randomized study published in the New England Journal of Medicine.

• Participants: The trial included 2,539 adult participants with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related complication, excluding diabetes.
• Administration: Participants received once-weekly subcutaneous injections of either Tirzepatide (5 mg, 10 mg, or 15 mg) or a placebo over a 72-week period.
• Primary Outcomes: The study measured the percentage change in body weight from the start of the trial. Data indicated that participants on the 15 mg dose experienced a mean weight reduction of approximately 20.9% to 22.5%.
• Adverse Events: The most frequently reported side effects were gastrointestinal in nature, including nausea, diarrhea, and constipation. These effects were generally categorized as mild to moderate and occurred most often during the dose-escalation phase.

Comparative evaluations, such as those discussed by the American Diabetes Association, note that Tirzepatide acts as a dual agonist, distinguishing it from single-hormone medications like semaglutide.

Tirzepatide is a first-in-class, single-molecule dual agonist that targets two specific gut hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

• Metabolic Regulation: By activating these receptors, the medication enhances glucose-dependent insulin secretion and suppresses glucagon levels, which helps stabilize blood sugar.
• Appetite and Satiety: Research highlighted in StatPearls via NCBI shows that Tirzepatide targets receptors in the brain involved in appetite regulation. It also slows gastric emptying, which increases the sensation of fullness after eating.

According to Drugs.com and clinical guidelines, Tirzepatide is not suitable for all individuals. Contraindications include:

• Personal or family history of Medullary Thyroid Carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Severe gastrointestinal disease or kidney impairment
• Pregnancy or breastfeeding

Use of this medication requires a prescription and regular supervision by a licensed healthcare provider to monitor for potential complications and ensure appropriate dosing.

• Tirzepatide Once Weekly for the Treatment of Obesity, NEJM.
• Insights into the Mechanism of Action of Tirzepatide, PMC.
• Tirzepatide Pharmacology, StatPearls.